Gw642138X

Gw642138X

SCHEMBL5404724

COc1ccc(-c2cc3c(N)ncnc3o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
EGFR P00533 8/20 0.57
GSK3B P49841 8/20 0.57
MAP4K4 O95819 1/20 0.56
KDR P35968 5/20 0.55
TEK Q02763 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5405208 0.84 GSK3B (0.52) EGFRGSK3BMAP4K4KDR
SCHEMBL6409547 0.83 EGFR (0.57) EGFRGSK3BKDR
SCHEMBL5403342 0.81 MAP4K4 (0.53) EGFRGSK3BMAP4K4KDR
SCHEMBL5412486 0.81 HPGD (0.54) EGFRGSK3BMAP4K4KDR
SCHEMBL1784311 0.80 HPGD (0.60) EGFRGSK3BMAP4K4KDR
SCHEMBL5450817 0.80 GSK3B (0.60) EGFRGSK3BKDR
SCHEMBL5655092 0.73 TEK (0.53) EGFRGSK3BMAP4K4KDRTEK
SCHEMBL5391001 0.73 GSK3B (1.00) EGFRGSK3BKDR
SCHEMBL15587273 0.72 MAP4K4 (1.00) MAP4K4
SCHEMBL8293366 0.71 GSK3B (1.00) GSK3BKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007513155-A 2007-05-24 JP claimed
US-20070088031-A1 Novel chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-04-19 US claimed
EP-1689753-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-08-16 EP claimed
WO-2005061516-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-07 WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 US disclosed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed
US-20070088031-A1 Novel chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-04-19 US disclosed
US-20070088031-A1 Novel chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-04-19 US disclosed
US-20070088031-A1 Novel chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-04-19 US disclosed
EP-1689753-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-08-16 EP disclosed
WO-2005061516-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-07 WO disclosed
WO-2005061516-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR EGFR 47/4885GSK3B 1284/4885MAP4K4 554/4885
US-20070088031-A1 Novel chemical compounds GSK3B, GSK3A, GSKIP EGFR 2349/4885GSK3B 1/4885MAP4K4 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.